Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, Friday said the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for Balversa for the treatment of patients with unresectable or metastatic urothelial carcinoma (UC).
The positive CHMP opinion is supported by data from Cohort 1 of the Phase 3 THOR study, which showed a 36 percent reduction in the risk of death with Balversa versus chemotherapy.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.